TNNT2 and breast carcinoma: Another study on the cardiotoxicity of anthracyclines in breast cancer patients (56) also showed that anthracyclines can increase hs-cTnT levels, and that an increase in hs-cTnT levels at the end of anthracycline therapy may indicate subsequent cardiotoxicity.